Factor V at Dr. Essa Lab

Factor V at Dr. Essa Lab

The Factor V test is a highly specialized coagulation assay designed to measure the functional activity of clotting Factor V (also known as proaccelerin or labile factor) in the blood. Coagulation is a complex, finely tuned physiological process involving a cascade of proteins that work in tandem to form a stable blood clot and prevent excessive bleeding following vascular injury. Factor V plays a pivotal role in this cascade, specifically within the common pathway of coagulation. Synthesized primarily by hepatocytes in the liver and stored additionally in platelet alpha-granules, Factor V acts as an essential cofactor. When activated to Factor Va by thrombin, it binds with activated Factor X (Xa) on phospholipid membranes in the presence of calcium ions to form the prothrombinase complex. This complex is extraordinarily efficient, accelerating the conversion of prothrombin to thrombin by several hundred thousand-fold. A precise assessment of Factor V activity is therefore critical for diagnosing inherited or acquired bleeding disorders, evaluating complex coagulopathies, and monitoring liver synthetic function.

At Dr. Essa Laboratory and Diagnostic Centre, Pakistan’s premier diagnostic institution founded in Karachi, we utilize advanced automated coagulation analyzers to perform the Factor V assay with exceptional precision. This test is invaluable for patients presenting with unexplained bruising, prolonged bleeding, or abnormal screening tests such as Prothrombin Time (PT) and Activated Partial Thromboplastin Time (aPTT). By measuring the percentage of active Factor V in a patient’s plasma relative to a standardized normal control, our expert pathologists can pinpoint specific deficiencies or identify the presence of acquired inhibitors. Understanding the functional status of Factor V is essential not only for managing acute bleeding episodes but also for pre-operative planning and long-term hematological care.

Clinical Procedure: What to Expect

Patient Preparation

Proper patient preparation is essential to ensure the accuracy and reliability of coagulation testing, as clotting factors are highly sensitive to pre-analytical variables. Patients undergoing a Factor V test at Dr. Essa Lab should adhere to the following guidelines:

• No Fasting Required: Fasting is generally not necessary for this test. You may eat and drink normally prior to your appointment unless instructed otherwise by your physician.
• Medication Disclosure: It is critical to inform your healthcare provider and the laboratory staff of all medications you are currently taking, particularly anticoagulants (such as heparin, warfarin, or direct oral anticoagulants like rivaroxaban and apixaban), as these can significantly alter coagulation test results.
• Temporary Discontinuation: In some cases, and strictly under the guidance of your referring physician, you may be advised to temporarily discontinue blood-thinning medications for a specific period before the test.
• Hydration: Staying well-hydrated is recommended as it makes venipuncture easier and ensures a smooth blood draw.
• Avoid Strenuous Exercise: Refrain from vigorous physical activity immediately before the test, as physical stress can transiently alter clotting factor levels.

During the Procedure

The collection of a blood sample for a Factor V assay is a routine and safe procedure performed by our highly trained phlebotomists. The process involves the following steps:

• Patient Identification and Verification: The phlebotomist will confirm your identity and review your test requisition form to ensure all clinical details are correct.
• Positioning: You will be asked to sit comfortably in a blood collection chair and extend your arm.
• Vein Selection: The phlebotomist will inspect your arm, typically the crease of the elbow (antecubital fossa), to locate a suitable and prominent vein.
• Sanitization: The skin over the selected vein will be thoroughly cleansed with an antiseptic solution to prevent any risk of contamination.
• Tourniquet Application: A soft elastic band (tourniquet) will be applied around your upper arm to increase blood pressure in the veins, making them more visible and accessible.
• Venipuncture: A sterile, single-use needle will be gently inserted into the vein. You may feel a brief, mild pinch or stinging sensation.
• Sample Collection: Blood will be drawn into a specialized light blue-top tube containing sodium citrate. This anticoagulant preserves the clotting factors in an inactive state until testing begins. Precise filling of this tube is critical to maintain the correct 9:1 blood-to-anticoagulant ratio.
• Tourniquet Removal: The tourniquet will be released once sufficient blood is collected, and the needle will be gently withdrawn.
• Post-Puncture Care: A sterile cotton ball or gauze will be pressed against the puncture site, and a small bandage will be applied. You will be asked to apply gentle pressure for a few minutes to stop any localized bleeding.
• Duration: The entire sample collection process takes less than five minutes, and you can resume your normal daily activities immediately afterward.

When is a Factor V Performed?

Evaluation of Unexplained Bleeding and Easy Bruising

Physicians frequently request a Factor V assay when a patient exhibits clinical symptoms of a bleeding diathesis that cannot be explained by routine platelet counts or basic coagulation screens. Symptoms such as recurrent epistaxis (nosebleeds), gingival bleeding, menorrhagia (heavy menstrual bleeding), easy bruising (ecchymosis), or prolonged bleeding after minor surgical procedures or dental extractions warrant a detailed investigation of specific clotting factors. Because Factor V is a key component of the common pathway, a significant reduction in its activity impairs the body’s ability to generate thrombin and form a stable fibrin clot. Identifying a Factor V deficiency allows hematologists to formulate targeted treatment plans, which may include the administration of fresh frozen plasma (FFP) or specific hemostatic agents during bleeding episodes or prior to invasive procedures.

Assessment of Liver Synthetic Function and Hepatic Disease

The liver is the primary site of synthesis for the majority of coagulation factors, including Factor V. In patients with chronic liver disease, cirrhosis, acute hepatic necrosis, or liver failure, the synthetic capacity of hepatocytes is severely compromised, leading to a decline in circulating clotting factors. Measuring Factor V levels is highly useful in clinical hepatology because, unlike other coagulation factors such as Factors II, VII, IX, and X, Factor V synthesis does not depend on Vitamin K. Therefore, evaluating Factor V activity helps clinicians differentiate between Vitamin K deficiency (where Factor V remains normal but other factors are low) and true parenchymal liver disease (where Factor V is significantly reduced). It also serves as a critical prognostic marker in acute liver failure and is used to monitor graft function following liver transplantation.

Investigation of Disseminated Intravascular Coagulation (DIC)

Disseminated Intravascular Coagulation (DIC) is a life-threatening, systemic thrombohemorrhagic disorder characterized by widespread activation of the coagulation cascade, leading to microvascular thrombi and the subsequent consumption of platelets and clotting factors. As the coagulation factors are rapidly consumed, the patient becomes highly susceptible to severe, generalized bleeding. Factor V is highly sensitive to consumption during DIC. Measuring its activity levels, alongside other parameters like fibrinogen, D-dimer, and platelet count, helps clinicians assess the severity of consumption coagulopathy. A rapid decline in Factor V activity is a classic hallmark of acute DIC, and serial monitoring of this factor assists in evaluating the patient’s response to therapeutic interventions and supportive care.

Investigating Abnormal Screening Tests (Prolonged PT and aPTT)

Routine coagulation screening tests, specifically Prothrombin Time (PT) and Activated Partial Thromboplastin Time (aPTT), are designed to evaluate the extrinsic, intrinsic, and common pathways of coagulation. Because Factor V operates in the common pathway, a significant deficiency or the presence of an inhibitor will cause a prolongation of both PT and aPTT. When a patient presents with unexplained prolongation of both of these screening tests, a systematic diagnostic algorithm is initiated. This typically begins with a mixing study, followed by specific factor assays if the mixing study suggests a factor deficiency. Performing a quantitative Factor V assay is a crucial step in this diagnostic pathway to confirm or rule out a localized defect in the common pathway.

Detection of Acquired Factor V Inhibitors

Acquired Factor V deficiency is a rare but clinically significant condition caused by the development of autoantibodies (inhibitors) directed against Factor V. These inhibitors neutralize the functional activity of the protein, leading to mild-to-severe bleeding manifestations. Acquired Factor V inhibitors can develop spontaneously or may be associated with autoimmune diseases, malignancies, certain medications, surgical procedures, or exposure to bovine thrombin (previously used in surgical sealants). A Factor V assay, performed in conjunction with mixing studies and inhibitor titers (such as the Bethesda assay), is essential to detect and quantify these neutralizing antibodies, guiding the clinical team in selecting appropriate immunosuppressive and hemostatic therapies.

What Does a Factor V Detect?

The Factor V assay is a highly sensitive diagnostic tool that can detect a wide range of congenital, acquired, and transient clinical conditions. Specifically, this test is capable of identifying:

• Congenital Factor V Deficiency (Parahemophilia): A rare autosomal recessive bleeding disorder characterized by significantly reduced Factor V activity levels, leading to variable bleeding symptoms.
• Severe Liver Parenchymal Damage: Marked reduction in Factor V activity due to compromised hepatic synthetic function in conditions like cirrhosis or acute liver failure.
• Disseminated Intravascular Coagulation (DIC): Depleted Factor V levels resulting from systemic consumption of clotting factors during widespread microvascular thrombosis.
• Acquired Factor V Inhibitors: The presence of neutralizing autoantibodies that bind to Factor V and inhibit its role in the prothrombinase complex, causing severe bleeding.
• Vitamin K Deficiency Differentiation: Normal Factor V levels in the presence of decreased Factors II, VII, IX, and X, confirming a nutritional deficiency or warfarin effect rather than hepatic failure.
• Normal Coagulation Function: Factor V activity within the reference range (typically 70% to 150%), indicating adequate cofactor activity for normal clot formation.
• Mild Factor V Deficiency: Activity levels between 30% and 60%, which are usually asymptomatic and rarely cause spontaneous bleeding but may require caution during major surgery.
• Moderate Factor V Deficiency: Activity levels between 10% and 30%, associated with an increased risk of post-traumatic bleeding and prolonged bleeding after invasive procedures.
• Severe Congenital Deficiency: Activity levels below 10%, which can present with severe, potentially life-threatening spontaneous hemorrhages, including hemarthrosis and intracranial bleeding.
• Dilutional Coagulopathy: Reduced Factor V activity following massive blood transfusions where stored blood deficient in labile factors is administered without adequate plasma replacement.
• Primary Systemic Amyloidosis: Acquired deficiency of Factor V due to the adsorption of the clotting factor onto amyloid fibrils in tissues.
• Elevated Factor V Levels: Increased activity, sometimes observed as an acute-phase reactant during inflammation, pregnancy, or oral contraceptive use, which may contribute to a hypercoagulable state.
• Hepatic Graft Function Recovery: Rising Factor V activity levels post-liver transplantation, indicating successful engraftment and functional recovery of the donor liver.
• Myeloproliferative Neoplasms: Altered Factor V levels occasionally associated with underlying bone marrow disorders affecting megakaryocyte and platelet function.
• Transient Pediatric Inhibitors: Temporary, non-pathogenic Factor V inhibitors sometimes detected in children following viral infections, which resolve spontaneously without bleeding.
• Drug-Induced Coagulation Alterations: Falsely decreased or increased Factor V activity measurements due to the presence of direct oral anticoagulants (DOACs) or high-dose heparin in the sample.
• Post-Surgical Consumption: Transiently decreased Factor V levels immediately following major cardiothoracic or orthopedic surgeries due to localized clot formation and consumption.
• Autoimmune-Associated Coagulopathy: Reduced Factor V activity associated with systemic lupus erythematosus (SLE) or other connective tissue disorders.
• Neonatal Coagulation Status: Physiological variations in Factor V levels in newborns, which must be interpreted using age-specific reference intervals.
• Combined Factor V and Factor VIII Deficiency: A distinct, rare autosomal recessive disorder characterized by a moderate deficiency of both clotting factors due to a defect in their intracellular transport.

Turnaround Time and Report Access at Dr. Essa Lab

At Dr. Essa Laboratory and Diagnostic Centre, we understand that timely diagnostic results are critical for effective clinical decision-making, particularly when managing bleeding or clotting disorders. The Factor V assay is performed by our highly trained medical technologists using state-of-the-art automated coagulation systems. Under the strict supervision of consultant hematologists, each sample undergoes rigorous quality control to ensure the highest degree of accuracy. Typically, the turnaround time for specialized coagulation assays like Factor V is within 24 to 48 hours of sample collection. Once the analysis is complete and verified by our laboratory specialists, patients and their referring physicians can access the official reports online through the Dr. Essa Lab web portal or mobile application. Additionally, physical copies of the reports can be collected from any of our conveniently located diagnostic centers across Karachi and other major cities.

Factor V Findings Overview

The following table provides a general overview of the parameters evaluated during a Factor V assay and associated coagulation studies, along with their clinical interpretations:

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Factor V Functional Activity	70% to 150% of normal activity	Decreased activity (<70%) indicating congenital or acquired deficiency; Elevated activity (>150%) associated with acute phase response.
Prothrombin Time (PT)	11.0 to 13.5 seconds (may vary by reagent)	Prolonged PT in cases of significant Factor V deficiency or presence of specific inhibitors.
Activated Partial Thromboplastin Time (aPTT)	25.0 to 35.0 seconds (may vary by reagent)	Prolonged aPTT when Factor V activity drops below critical levels (typically <30%).
Mixing Studies (1:1 with Normal Plasma)	Correction of prolonged PT/aPTT to normal range	Failure to correct indicates the presence of a Factor V inhibitor (neutralizing antibody).
Thrombin Time (TT)	12.0 to 14.0 seconds (normal)	Normal TT in isolated Factor V deficiency, helping rule out fibrinogen abnormalities or heparin contamination.
Liver Function Tests (ALT, AST, Bilirubin)	All parameters within normal physiological limits	Elevated transaminases and bilirubin correlating with acquired Factor V deficiency due to hepatic parenchymal damage.
Fibrinogen Level	200 to 400 mg/dL	Decreased fibrinogen levels accompanying low Factor V in consumptive states like DIC.

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Dr. Essa Lab for Factor V?

• Highly Experienced Pathologists: Our laboratory is directed by renowned consultant pathologists and hematologists who oversee all coagulation testing and provide expert clinical interpretations.
• State-of-the-Art Coagulation Analyzers: We utilize advanced, fully automated photo-optical and mechanical clot detection systems to ensure maximum precision and reproducibility of results.
• ISO Certified Quality Standards: Dr. Essa Lab adheres to rigorous international quality control standards, ensuring that our diagnostic processes meet global benchmarks for accuracy.
• Convenient Home Sample Collection: Patients can avail themselves of our professional home phlebotomy services, allowing comfortable sample collection from the convenience of their homes in Karachi.
• Rapid and Secure Online Reports: Access your diagnostic reports securely through our user-friendly website or dedicated mobile application as soon as they are verified.
• Extensive Network of Centers: With numerous branches across Karachi and Pakistan, accessing our high-quality diagnostic services is convenient and hassle-free.
• Strict Pre-Analytical Protocols: We implement meticulous sample handling and temperature-controlled transport protocols to preserve labile clotting factors like Factor V.
• Patient-Centric Compassionate Care: Our dedicated staff is committed to providing a comfortable, safe, and professional environment for all patients undergoing diagnostic testing.